# Pini Orbach

> Pini Orbach is a Series B investor at Arkin Bio Ventures backing Medical and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures)
- Location: Tel Mond, Israel
- Total investments: 3
- Last investment: Mar 2026
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/pini-orbach-6bb6071/

Pini Orbach is a Series B investor at Arkin Bio Ventures in Tel Mond focused on Medical and Health Care. Pini Orbach is based out of Tel Mond, HaMerkaz, and is the Managing Partner of Arkin Bio Ventures and also a Member of the Board of Crossbow Therapeutics. Pini previously worked at Optimata as CEO. Pini Orbach attended the University of Florida College of Medicine

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Life Science | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Crossbow Therapeutics | Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M | Series B | Mar 18, 2026 |  |
| Nocion Therapeutics | Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $23M | Series B | Jan 07, 2026 |  |
| Nocion Therapeutics | Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation. The company is developing "nocions" which are a new kind of therapy that selectively affects actively firing nociceptors, enabling patients to provide targeted, robust and sustained relief for the treatment ofserious conditions including cough, itch, pain and inflammation. | $62M | Series B | Mar 04, 2024 |  |

3 of 3 investments shown.

## Co-investors
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 2 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 2 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 2 deals together
- [Mass General Brigham Ventures](https://shizune.co/investors/profile/mass-general-brigham-ventures) — VC Fund, 2 deals together
- [Monograph Capital](https://shizune.co/investors/profile/monograph-capital) — VC Fund, 2 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 2 deals together

## About Arkin Bio Ventures

VC Fund · Herzliya, Israel

Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies.

1 contacts available at Arkin Bio Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Pini Orbach | Managing Partner | https://shizune.co/investors/profile/pini-orbach |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Pini Orbach invest in?

Pini Orbach invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Pini Orbach last invest?

The most recent investment recorded for Pini Orbach closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co